Stemmler HJ - Search Results

1

Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. Hofer S, et al. Among authors: stemmler hj. Acta Oncol. 2012 Sep;51(7):955-6. doi: 10.3109/0284186X.2012.673736. Epub 2012 Apr 23. Acta Oncol. 2012. PMID: 22524214 No abstract available.

2

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.

Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V. Stemmler HJ, et al. Anticancer Drugs. 2008 Sep;19(8):832-6. doi: 10.1097/CAD.0b013e32830b58b0. Anticancer Drugs. 2008. PMID: 18690096

3

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Stemmler HJ, et al. Anticancer Drugs. 2007 Jan;18(1):23-8. doi: 10.1097/01.cad.0000236313.50833.ee. Anticancer Drugs. 2007. PMID: 17159499

4

Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.

Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lässig D, Schoenberg S, Heinemann V. Stemmler HJ, et al. Oncol Rep. 2006 May;15(5):1373-7. doi: 10.3892/or.15.5.1373. Oncol Rep. 2006. PMID: 16596213

5

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.

Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ. Heinemann V, et al. Among authors: stemmler hj. Ann Oncol. 2011 Mar;22(3):603-608. doi: 10.1093/annonc/mdq409. Epub 2010 Aug 19. Ann Oncol. 2011. PMID: 20724574 Free article. Clinical Trial.

6

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).

Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Stemmler HJ, et al. Onkologie. 2005 Nov;28(11):582-6. doi: 10.1159/000088296. Onkologie. 2005. PMID: 16249644

7

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.

Stemmler HJ, Heinemann V. Stemmler HJ, et al. Oncologist. 2008 Jul;13(7):739-50. doi: 10.1634/theoncologist.2008-0052. Epub 2008 Jul 9. Oncologist. 2008. PMID: 18614587 Free article. Review.

8

Anticancer therapy induced cardiotoxicity: review of the literature.

Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Geiger S, et al. Among authors: stemmler hj. Anticancer Drugs. 2010 Jul;21(6):578-90. doi: 10.1097/CAD.0b013e3283394624. Anticancer Drugs. 2010. PMID: 20375725 Review.

9

Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.

Geiger S, Cnossen JA, Horster S, DiGioia D, Heinemann V, Stemmler HJ. Geiger S, et al. Among authors: stemmler hj. Anticancer Drugs. 2011 Oct;22(9):933-9. doi: 10.1097/CAD.0b013e32834860af. Anticancer Drugs. 2011. PMID: 21666437

10

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.

Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, Stemmler HJ, Kirchner T, Heinemann V. Modest DP, et al. Among authors: stemmler hj. Anticancer Drugs. 2011 Oct;22(9):913-8. doi: 10.1097/CAD.0b013e3283493160. Anticancer Drugs. 2011. PMID: 21795973 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page